Skip to main content
Figure 5 | Journal of Translational Medicine

Figure 5

From: T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein

Figure 5

Pharmacodynamic markers correlative evaluation with patient survival. (A) Kaplan-Meier Survival Curve with 95% confidence limits stratified by lymphocyte counts (cell/mm3) at baseline in patient groups 1 and 2. (B) Kaplan-Meier Survival Curve with 95% confidence limits stratified by percent of activated CD8+ T-cells (CD38+bcl2-,%) at baseline in patient groups 1 and 2. (C) Kaplan-Meier Survival Curve with 95% confidence limits stratified by absolute count of activated CD8+ T-cells (CD38+bcl2-, Cell/mm3) at baseline in patient groups 1 and 2.

Back to article page